GT200900333A - Compuestos de quinolina adecuados para el tratamiento de transtornos que responden a la modulación del receptor de serotonina 5-ht6. - Google Patents

Compuestos de quinolina adecuados para el tratamiento de transtornos que responden a la modulación del receptor de serotonina 5-ht6.

Info

Publication number
GT200900333A
GT200900333A GT200900333A GT200900333A GT200900333A GT 200900333 A GT200900333 A GT 200900333A GT 200900333 A GT200900333 A GT 200900333A GT 200900333 A GT200900333 A GT 200900333A GT 200900333 A GT200900333 A GT 200900333A
Authority
GT
Guatemala
Prior art keywords
compounds
serotonine
modulation
receiver
kinoline
Prior art date
Application number
GT200900333A
Other languages
English (en)
Inventor
turner Sean
Braje Wilfried
Haupt Andreas
Lange Udo
Drescher Karla
Wicke Karsten
Unger Liliane
Mezler Mario
Wernet Wolfgang
Mayrer Mathias
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200900333A publication Critical patent/GT200900333A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

LA PRESENTE INVENCIÓN SE RELACIONA CON NUEVOS COMPUESTOS DE QUINOLINA DE LA FÓRMULA I Y SALES DE LOS MISMOS. LOS COMPUESTOS TIENEN PROPIEDADES TERAPÉUTICAS VALIOSAS Y SON APROPIADOS, EN PARTICULAR, PARA TRATAR ENFERMEDADES QUE RESPONDEN A LA MODULACIÓN DEL RECEPTOR DE SEROTONINA 5-HT6. EN LA FÓRMULA I, R ES UNA PORCIÓN DE LA FÓRMULA EN DONDE * INDICA EL SITIO DE UNIÓN AL RADICAL QUINOLINILO Y EN DONDE A,B,X',Y,Q,R1,R2,R3,R4,R5,M,N,P,Q,RA, RB,X Y AR SON COMO SE DEFINEN EN LA REIVINDICACIÓN 1.
GT200900333A 2007-08-07 2009-12-29 Compuestos de quinolina adecuados para el tratamiento de transtornos que responden a la modulación del receptor de serotonina 5-ht6. GT200900333A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07113962 2007-08-07

Publications (1)

Publication Number Publication Date
GT200900333A true GT200900333A (es) 2015-10-14

Family

ID=39809897

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200900333A GT200900333A (es) 2007-08-07 2009-12-29 Compuestos de quinolina adecuados para el tratamiento de transtornos que responden a la modulación del receptor de serotonina 5-ht6.

Country Status (23)

Country Link
US (2) US8293913B2 (es)
EP (1) EP2185555B1 (es)
JP (1) JP5501230B2 (es)
KR (1) KR20100039300A (es)
CN (1) CN101687866B (es)
AU (1) AU2008285652B2 (es)
BR (1) BRPI0812853A2 (es)
CA (1) CA2691529C (es)
CO (1) CO6251268A2 (es)
CR (1) CR11187A (es)
DO (1) DOP2009000291A (es)
EC (1) ECSP099831A (es)
ES (1) ES2574154T3 (es)
GT (1) GT200900333A (es)
HK (1) HK1143588A1 (es)
IL (1) IL202706A (es)
MX (1) MX2009013956A (es)
NZ (1) NZ581986A (es)
RU (1) RU2483068C2 (es)
TW (1) TWI478919B (es)
UA (1) UA99626C2 (es)
WO (1) WO2009019286A1 (es)
ZA (1) ZA200909075B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
MA38982A1 (fr) 2013-11-26 2017-09-29 Hoffmann La Roche Nouvel octahydro-cyclobuta [1,2-c; 3,4-c'] dipyrrol-2-yl
CN106103446B (zh) 2014-03-26 2019-07-30 豪夫迈·罗氏有限公司 作为自分泌运动因子(atx)和溶血磷脂酸(lpa)生产抑制剂的二环化合物
KR102315014B1 (ko) * 2014-04-30 2021-10-20 카티바, 인크. 가스 쿠션 장비 및 기판 코팅 기술
CN108026077B (zh) 2015-09-04 2021-11-05 豪夫迈·罗氏有限公司 苯氧基甲基衍生物
MA42923A (fr) * 2015-09-24 2021-04-28 Hoffmann La Roche Composés bicycliques comme inhibiteurs mixtes de atx/ca
MA42918A (fr) 2015-09-24 2018-08-01 Hoffmann La Roche Composés bicycliques utilisés en tant qu'inhibiteurs d'atx
WO2017050792A1 (en) 2015-09-24 2017-03-30 F. Hoffmann-La Roche Ag Bicyclic compounds as atx inhibitors
JP6845230B2 (ja) * 2015-09-24 2021-03-17 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ デュアルａｔｘ／ｃａ阻害剤としての新規な二環式化合物
AR106515A1 (es) * 2015-10-29 2018-01-24 Bayer Cropscience Ag Sililfenoxiheterociclos trisustituidos y análogos
WO2017157929A1 (en) * 2016-03-14 2017-09-21 AbbVie Deutschland GmbH & Co. KG Quinoline compounds suitable for treating disorders that respond to the modulation of the serotonin 5-ht6 receptor
MA49879A (fr) 2017-03-16 2020-06-24 Hoffmann La Roche Composés hétérocycliques utiles en tant qu'inhibiteurs doubles d'atx/ca
CN110382484B (zh) 2017-03-16 2022-12-06 豪夫迈·罗氏有限公司 新的作为atx抑制剂的二环化合物
JP7390401B2 (ja) * 2019-05-30 2023-12-01 シャンハイ インスティテュート オブ マテリア メディカ、チャイニーズ アカデミー オブ サイエンシーズ 縮合環化合物、その製造方法及び用途
CN117561058A (zh) * 2021-06-26 2024-02-13 塞迪拉治疗股份有限公司 Cdk2抑制剂及其使用方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0861236T4 (da) * 1995-11-13 2006-12-18 Sanofi Aventis Deutschland Cykliske og heterocykliske N-substituerede alphaiminohydroxam- og carboxylsyrer
GB9803411D0 (en) * 1998-02-18 1998-04-15 Smithkline Beecham Plc Novel compounds
DE10000739A1 (de) 2000-01-11 2001-07-12 Merck Patent Gmbh Piperidin- und Piperazinderivate
PL209872B1 (pl) * 2002-03-27 2011-10-31 Glaxo Group Ltd Pochodna chinolinowa, sposób jej wytwarzania i jej zastosowanie oraz zawierająca ją farmaceutyczna kompozycja
GB0321473D0 (en) * 2003-09-12 2003-10-15 Glaxo Group Ltd Novel compounds
GB0322510D0 (en) * 2003-09-25 2003-10-29 Glaxo Group Ltd Novel compounds
CA2543710A1 (en) * 2003-11-03 2005-05-12 Warner-Lambert Company Llc Novel norepinephrine reuptake inhibitors for the treatment of central nervous system disorders
GB0411421D0 (en) * 2004-05-21 2004-06-23 Glaxo Group Ltd Novel compounds
DE102004038268A1 (de) * 2004-08-06 2006-03-16 Sanofi-Aventis Deutschland Gmbh Substituierte, bizyklische 8-Pyrrolidino-xanthine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
GB0425548D0 (en) 2004-11-19 2004-12-22 Glaxo Group Ltd Radiolabelled ligands
WO2006113704A2 (en) * 2005-04-18 2006-10-26 Neurogen Corporation Subtituted heteroaryl cb1 antagonists
ES2341489T3 (es) * 2005-07-27 2010-06-21 F.Hoffmann-La Roche Ag Derivados de 4-ariloxi quinolina como moduladores de 5-ht6.
GB0519765D0 (en) 2005-09-28 2005-11-09 Glaxo Group Ltd Novel compounds

Also Published As

Publication number Publication date
ZA200909075B (en) 2013-03-27
NZ581986A (en) 2012-02-24
ECSP099831A (es) 2010-01-29
CR11187A (es) 2010-05-27
EP2185555A1 (en) 2010-05-19
KR20100039300A (ko) 2010-04-15
CA2691529A1 (en) 2009-02-12
CO6251268A2 (es) 2011-02-21
EP2185555B1 (en) 2016-03-16
IL202706A0 (en) 2010-06-30
CN101687866B (zh) 2014-06-04
UA99626C2 (ru) 2012-09-10
WO2009019286A1 (en) 2009-02-12
CA2691529C (en) 2016-01-05
AU2008285652B2 (en) 2013-09-05
ES2574154T3 (es) 2016-06-15
TWI478919B (zh) 2015-04-01
DOP2009000291A (es) 2010-01-31
MX2009013956A (es) 2010-04-30
US20100292271A1 (en) 2010-11-18
JP5501230B2 (ja) 2014-05-21
US8293913B2 (en) 2012-10-23
IL202706A (en) 2014-08-31
CN101687866A (zh) 2010-03-31
RU2483068C2 (ru) 2013-05-27
HK1143588A1 (zh) 2011-01-07
AU2008285652A1 (en) 2009-02-12
RU2010108282A (ru) 2011-09-20
TW200914453A (en) 2009-04-01
BRPI0812853A2 (pt) 2014-12-23
JP2010535739A (ja) 2010-11-25
US20130005703A1 (en) 2013-01-03
US8440694B2 (en) 2013-05-14

Similar Documents

Publication Publication Date Title
GT200900333A (es) Compuestos de quinolina adecuados para el tratamiento de transtornos que responden a la modulación del receptor de serotonina 5-ht6.
UY31402A1 (es) "piperazino-dihidrotienopirimidinas sustituidas en heterociclo"
BRPI0818006B8 (pt) compostos de piperidino-di-hidrotienopirimidinas substituídas, uso dos mesmos e formulações farmacêuticas
CO6491058A2 (es) Derivados de oxazina y su uso como inhibidores de bace para el tratamiento de trastornos neurológicos
UY33779A (es) ?2-(fenilamino)-1H-bencimidazol-5-carboxamidas novedosas?
ECSP109903A (es) Derivados de pirazinona y su uso en el tratamiento de enfermedades pulmonares
ECSP12012065A (es) Derivados de pirazina y su uso en el tratamiento de trastornos neurológicos
CR20120591A (es) Derivados de aminopirimidina como moduladores de la lrrk2
EA201290184A1 (ru) Бензодиазепиновый ингибитор бромодомена
BR112014026176A2 (pt) dipiridilaminas substituídas e usos das mesmas
CU20090132A7 (es) Compuestos tricíclicos, composiciones y procedimientos
BRPI0608387A2 (pt) compostos para o tratamento de doenças inflamatórias
ECSP088969A (es) Amino-imidazolones y su uso como medicamento para tratar deficiencias cognitivas, enfermedad de alzheimer, neurodegeneración y demencia
ATE541832T1 (de) Neuartige p2x7r-antagonisten und ihre verwendung
EA201390163A1 (ru) Гетеробициклические производные в качетстве ингибиторов hcv
EA201500403A1 (ru) Соединения, активирующие теломеразу, и способы их применения
UY31159A1 (es) Derivados de quinolina, métodos para su fabricación, composiciones farmacéuticas de los mismos y usos de los mismos
EA201000362A1 (ru) Производные 1,3-дигидроизоиндола
AR061637A1 (es) Composiciones y metodos de tratamiento de trastornos del snc
ATE521609T1 (de) Aminothiazolylpyrimidinderivate und ihre verwendung bei der behandlung von krebs
CL2009000445A1 (es) Compuestos derivados de piperidina 1,4 heterociclo sustituidos, procedimiento para preparar estos compuestos, composicion farmaceutica que los comprende y su uso para la terapia del dolor y el tratamiento de enfermedades como alzheimer, esquizofrenia, ansiedad y depresion.
EA200970849A1 (ru) Трициклические производные изохинолина для лечения ожирения
DOP2007000077A (es) Compuestos heterocíclicos apropiados para tratar trastornos que responden a la modulación del receptor de serotonina 5ht6.
EA201390398A1 (ru) Арилсульфонамиды для лечения заболеваний цнс
UY31326A (es) Compuestos de quinolina apropiados para tratar trastornos que responden a la modulación del receptor de serotonina 5-ht6